ACHV
NASDAQ · Biotechnology
Achieve Life Sciences Inc
$6.32
+0.03 (+0.48%)
Open$6.30
Previous Close$6.29
Day High$6.43
Day Low$5.93
52W High$8.64
52W Low$2.62
Volume—
Avg Volume1.24M
Market Cap697.68M
P/E Ratio—
EPS$-1.55
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+404.6% upside
Current
$6.32
$6.32
Target
$31.89
$31.89
$22.93
$31.89 avg
$41.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 55.16B | 99.69B | 656.40M |
| Net Income | -136,646,939 | -222,270,459 | 10.36M |
| Profit Margin | -397.8% | -377.9% | 1.6% |
| EBITDA | -137,235,606 | -235,629,542 | 18.53M |
| Free Cash Flow | — | — | 6.70M |
| Rev Growth | -44.7% | -44.7% | +1.9% |
| Debt/Equity | 0.69 | 0.69 | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.55 | -0.16% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $456.60 | -1.24% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $169.42 | +1.10% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $531.97 | -1.08% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $951.08 | -0.14% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $159.73 | -3.22% | 7.7 | 20.98B |